Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins

Author(s): Zlatko Fras*

Volume 19, Issue 4, 2021

Published on: 16 February, 2021

Page: [398 - 402] Pages: 5

DOI: 10.2174/157016111904210216104403

« Previous Next »
[1]
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459-72.
[http://dx.doi.org/10.1093/eurheartj/ehx144] [PMID: 28444290]
[2]
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019; 73(24): 3168-209.
[http://dx.doi.org/10.1016/j.jacc.2018.11.002] [PMID: 30423391]
[3]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[4]
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[5]
Agouridis AP, Mikhailidis DP. Should we consider ezetimibe to reach even lower LDL-C targets? Curr Med Res Opin 2015; 31(3): 459-60.
[http://dx.doi.org/10.1185/03007995.2015.1005204] [PMID: 25565356]
[6]
Laufs U, Isermann B. Statin intolerance: myths and facts. Eur Heart J 2020; 41(35): 3343-5.
[http://dx.doi.org/10.1093/eurheartj/ehaa582] [PMID: 32702749]
[7]
Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J 2016; 37(11): 908-16.
[http://dx.doi.org/10.1093/eurheartj/ehv641] [PMID: 26643266]
[8]
Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1-23.
[http://dx.doi.org/10.5114/aoms.2015.49807] [PMID: 25861286]
[9]
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and Management. Eur Heart J 2015; 36(17): 1012-22.
[http://dx.doi.org/10.1093/eurheartj/ehv043] [PMID: 25694464]
[10]
Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014; 8(3)(Suppl.): S72-81.
[http://dx.doi.org/10.1016/j.jacl.2014.03.002] [PMID: 24793444]
[11]
Snejdrlova M, Altschmiedova T, Vrablik M, et al. Statin Intolerance in Clinical Practice. Curr Atheroscler Rep 2020; 22(7): 27.
[http://dx.doi.org/10.1007/s11883-020-00845-9] [PMID: 32495058]
[12]
Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol 2016; 67(20): 2395-410.
[http://dx.doi.org/10.1016/j.jacc.2016.02.071] [PMID: 27199064]
[13]
Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21(4): 464-74.
[http://dx.doi.org/10.1177/2047487314525531] [PMID: 24623264]
[14]
Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med 2019; 9(1): 22.
[http://dx.doi.org/10.3390/jcm9010022] [PMID: 31861911]
[15]
Hamann PD, Cooper RG, McHugh NJ, Chinoy H. Statin-induced necrotizing myositis - a discrete autoimmune entity within the “statin-induced myopathy spectrum”. Autoimmun Rev 2013; 12(12): 1177-81.
[http://dx.doi.org/10.1016/j.autrev.2013.07.001] [PMID: 23851103]
[16]
Robinson JG. New insights into managing symptoms during statin therapy. Prog Cardiovasc Dis 2019; 62(5): 390-4.
[http://dx.doi.org/10.1016/j.pcad.2019.10.005] [PMID: 31669768]
[17]
Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013; 166(3): 597-603.
[http://dx.doi.org/10.1016/j.ahj.2013.06.004] [PMID: 24016512]
[18]
Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101(4): 483-5.
[http://dx.doi.org/10.1016/j.amjcard.2007.09.096] [PMID: 18312762]
[19]
Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 2015; 7(3): 86-93.
[http://dx.doi.org/10.4103/1947-2714.153919] [PMID: 25838999]
[20]
Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 2015; 99: 329-36.
[http://dx.doi.org/10.1016/j.phrs.2015.07.008] [PMID: 26192349]
[21]
Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015; 238(2): 329-35.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.12.016] [PMID: 25545331]
[22]
Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015; 90(1): 24-34.
[http://dx.doi.org/10.1016/j.mayocp.2014.08.021] [PMID: 25440725]
[23]
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23(9): 2183-92.
[http://dx.doi.org/10.1185/030079907X226267] [PMID: 17692154]
[24]
Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265(5): 568-80.
[http://dx.doi.org/10.1111/j.1365-2796.2008.02062.x] [PMID: 19141093]
[25]
Tomlinson B, Chan P, Zhang Y, Lam CWK. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opin Pharmacother 2020; 21(17): 2137-51.
[http://dx.doi.org/10.1080/14656566.2020.1801638] [PMID: 32772741]
[26]
Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63(23): 2531-40.
[http://dx.doi.org/10.1016/j.jacc.2014.03.018] [PMID: 24691094]
[27]
Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol 2019; 74(17): 2132-46.
[http://dx.doi.org/10.1016/j.jacc.2019.08.1024] [PMID: 31648705]
[28]
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1489-99.
[http://dx.doi.org/10.1056/NEJMoa1501031] [PMID: 25773378]
[29]
Robinson JG, Farnier M, Kastelein JJP, et al. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. J Clin Lipidol 2019; 13(6): 979-988.e10.
[http://dx.doi.org/10.1016/j.jacl.2019.10.004] [PMID: 31708410]
[30]
Benhuri B, Ueyama H, Takagi H, Briasoulis A, Kuno T. PCSK9 inhibitors and ezetimibe monotherapy in patients not receiving statins: a meta-analysis of randomized trials. Curr Vasc Pharmacol 2021; 19(4): 390-7.
[PMID: 32767943]
[31]
Koren MJ, Jones PH, Robinson JG, et al. A comparison of ezetimibe and evolocumab for atherogenic lipid reduction in four patient populations: a pooled efficacy and safety analysis of three phase 3 studies. Cardiol Ther 2020; 9(2): 447-65.
[http://dx.doi.org/10.1007/s40119-020-00181-8] [PMID: 32564340]
[32]
Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014; 176(1): 55-61.
[http://dx.doi.org/10.1016/j.ijcard.2014.06.049] [PMID: 25037695]
[33]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[34]
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097-107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]
[35]
Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol 2020; 14(1): 88-97.e2.
[http://dx.doi.org/10.1016/j.jacl.2020.01.001] [PMID: 32192644]
[36]
Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308(23): 2497-506.
[http://dx.doi.org/10.1001/jama.2012.25790] [PMID: 23128163]
[37]
Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63(23): 2541-8.
[http://dx.doi.org/10.1016/j.jacc.2014.03.019] [PMID: 24694531]
[38]
Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016; 315(15): 1580-90.
[http://dx.doi.org/10.1001/jama.2016.3608] [PMID: 27039291]
[39]
Hollstein T, Kassner U, Grenkowitz T, Schumann F, Bobbert T, Steinhagen-Thiessen E. PCSK9 inhibitors in a german single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks. Am J Cardiovasc Drugs 2021; 21(1): 83-92.
[http://dx.doi.org/10.1007/s40256-020-00411-3] [PMID: 32514867]
[40]
Fras Z, Mikhailidis DP. Have we learnt all from IMPROVE-IT? Part II. Subanalyses on the effects of ezetimibe added to statin therapy on selected clinical and laboratory outcomes, cost effectiveness, guideline and clinical implications. Curr Vasc Pharmacol 2020.
[PMID: 32720603]
[41]
Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457.
[http://dx.doi.org/10.1038/ncomms13457] [PMID: 27892461]
[42]
Markham A. Bempedoic Acid: First Approval. Drugs 2020; 80(7): 747-53.
[http://dx.doi.org/10.1007/s40265-020-01308-w] [PMID: 32314225]
[43]
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380(11): 1022-32.
[http://dx.doi.org/10.1056/NEJMoa1803917] [PMID: 30865796]
[44]
Di Minno A, Lupoli R, Calcaterra I, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2020; 9(15)e016262
[http://dx.doi.org/10.1161/JAHA.119.016262] [PMID: 32689862]
[45]
Cicero AFG, Fogacci F, Hernandez AV, Banach M. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med 2020; 17(7)e1003121
[http://dx.doi.org/10.1371/journal.pmed.1003121] [PMID: 32673317]
[46]
German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs 2020; 34(1): 1-9.
[http://dx.doi.org/10.1007/s40259-019-00399-6] [PMID: 31782112]
[47]
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382(16): 1507-19.
[http://dx.doi.org/10.1056/NEJMoa1912387] [PMID: 32187462]
[48]
Catapano AL, Pirillo A, Norata GD. Insights from ORION studies: focus on inclisiran safety. Cardiovasc Res 2021; 117(1): 24-6.
[PMID: 32402083]
[49]
Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: a cost-effectiveness analysis. Pharmacoeconomics 2020; 38(9): 1007-20.
[http://dx.doi.org/10.1007/s40273-020-00948-w] [PMID: 32789593]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy